BPMC News and Press, Blueprint Medicines Corporation From 05/06/20

Blueprint Medicines Corporation (BPMC) Q1 2020 Earnings Conference Call May 6, 2020, 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Mike Landsittel - CFO Andy Boral - Chief Medical Officer Con...

Blueprint Medicines  (NASDAQ: BPMC ): Q1 GAAP EPS of -$2.11 beats by $0.05 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , May 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the first qua...

Aurinia Pharmaceuticals (AUP CN) initiated with Outperform rating and C$30 (29% upside) price target at Cowen and Company. No premarket activity yet (NASDAQ: AUPH ) in U.S. More news on: Aurinia Pharmaceuticals Inc., Blueprint Medicines Corporation, Cytokinetics, Incorporated, Healthcare s...

CAMBRIDGE, Mass. , April 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ...

Gainers: Creative Realities (NASDAQ: CREX ) +125% . More news on: Creative Realities, Inc., Syndax Pharmaceuticals, Inc., Kura Oncology, Inc., Stocks on the move, , Read more ...

Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free...

NeuBase Therapeutics (NASDAQ: NBSE )  -15%  on equity offering . More news on: NeuBase Therapeutics, Inc., Yield10 Bioscience, Inc., Blueprint Medicines Corporation, Stocks on the move, , Read more ...

Blueprint Medicines (NASDAQ: BPMC ) slumps  15%  premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER , evaluating lead candidate avapritinib, branded as Ayvakit, in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) failed to...

CAMBRIDGE, Mass. , April 28, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avaprit...